1. Measured by its binding ability in a functional ELISA. Immobilized cynomolgus IL-13 at 4 μg/ml (100 μl/well) can bind human IL13RA1 with a linear range of 0.156-2.5 μg/ml. 2. Measured in a cell proliferation assay using TF1 human erythroleukemic cells. The ED50 for this effect is typically 100-400 ng/mL.

IL-13 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 14.5 kDa and the accession number is Q0PW92.

Cynomolgus

HEK293 Cells

interleukin 13

The mature form of Cynomolgus (Macaca fascicularis) IL-13 (ABG75889.1) (Ser 21-Asn 132) was fused with a polyhistidine tag at the N-terminus.

> 95 % as determined by SDS-PAGE

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Interleukin 13 (IL-13) is a single-chain glycosylated polypeptide, which belongs to the IL-13/IL-4 family. IL-13 protein is secreted by many cell types, but especially by T helper type 2 (Th2) cells. IL-13 exerts its effects through a multi-subunit receptor comprising the alpha chain of the IL-4 receptor (IL-4Rα) and at least one of two known IL-13-specific binding chains (IL-13 Rα1 and IL-13 Rα2). As a cytokine, IL-13 protein is critical in regulating inflammatory, immune responses, and diseases. Also, it inhibits the production of pro-inflammatory cytokines and chemokines, and thus down-regulates macrophage activity. IL-13 protein and antibody are more importantly implicated as a central mediator of immunoregulatory processes in various cell types.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy